Form 8-K - Current report:
SEC Accession No. 0001178913-23-002225
Filing Date
2023-06-16
Accepted
2023-06-16 16:01:35
Documents
13
Period of Report
2023-06-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K zk2329883.htm   iXBRL 8-K 33141
  Complete submission text file 0001178913-23-002225.txt   215828

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20230614.xsd EX-101.SCH 4643
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20230614_def.xml EX-101.DEF 18313
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20230614_lab.xml EX-101.LAB 28539
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20230614_pre.xml EX-101.PRE 20555
7 EXTRACTED XBRL INSTANCE DOCUMENT zk2329883_htm.xml XML 6617
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 231020856
SIC: 2834 Pharmaceutical Preparations